Silo Pharma Files 8-K: Other Events & Exhibits
Ticker: SILO · Form: 8-K · Filed: Apr 5, 2024 · CIK: 1514183
| Field | Detail |
|---|---|
| Company | Silo Pharma, Inc. (SILO) |
| Form Type | 8-K |
| Filed Date | Apr 5, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001, $1.0 million, $566,803 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, filing, corporate-update
TL;DR
Silo Pharma dropped an 8-K on 4/4/24 covering other events and financials.
AI Summary
On April 4, 2024, Silo Pharma, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." The company, formerly known as Uppercut Brands, Inc., Point Capital, Inc., and Gold Swap Inc., is incorporated in Nevada and headquartered in Sarasota, Florida.
Why It Matters
This 8-K filing indicates that Silo Pharma, Inc. is providing updates on significant company events and financial information to the SEC, which is crucial for investors to stay informed about the company's status.
Risk Assessment
Risk Level: low — This filing is a standard 8-K reporting routine events and exhibits, not indicating any immediate financial distress or significant new risks.
Key Players & Entities
- Silo Pharma, Inc. (company) — Registrant
- Uppercut Brands, Inc. (company) — Former company name
- Point Capital, Inc. (company) — Former company name
- Gold Swap Inc (company) — Former company name
- April 4, 2024 (date) — Date of earliest event reported
FAQ
What is the primary purpose of this 8-K filing for Silo Pharma, Inc.?
The primary purpose of this 8-K filing is to report on "Other Events" and "Financial Statements and Exhibits" as of April 4, 2024.
When was the earliest event reported in this filing?
The earliest event reported in this filing occurred on April 4, 2024.
What are some of the former names of Silo Pharma, Inc. mentioned in the filing?
The filing mentions that Silo Pharma, Inc. was formerly known as Uppercut Brands, Inc., Point Capital, Inc., and Gold Swap Inc.
In which state is Silo Pharma, Inc. incorporated?
Silo Pharma, Inc. is incorporated in Nevada.
What is the principal executive office address for Silo Pharma, Inc.?
The principal executive office address for Silo Pharma, Inc. is 677 N. Washington Boulevard, Sarasota, FL 34236.
Filing Stats: 452 words · 2 min read · ~2 pages · Grade level 11 · Accepted 2024-04-05 16:01:16
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share SILO The Nasdaq Stock Mar
- $1.0 million — ogram authorizing the purchase of up to $1.0 million of the Company's common stock until Apr
- $566,803 — of its common stock for a total cost of $566,803 pursuant to its Stock Repurchase Progra
Filing Documents
- ea0203400-8k_silopharma.htm (8-K) — 25KB
- 0001213900-24-030805.txt ( ) — 191KB
- silo-20240404.xsd (EX-101.SCH) — 3KB
- silo-20240404_lab.xml (EX-101.LAB) — 33KB
- silo-20240404_pre.xml (EX-101.PRE) — 22KB
- ea0203400-8k_silopharma_htm.xml (XML) — 3KB
01 – Other Events
Item 8.01 – Other Events On April 4, 2024, the Board of Directors of Silo Pharma, Inc. (the "Company") approved an extension of the previously announced stock repurchase program authorizing the purchase of up to $1.0 million of the Company's common stock until April 30, 2024. As of March 31, 2024, the Company had repurchased an aggregate of 315,462 shares of its common stock for a total cost of $566,803 pursuant to its Stock Repurchase Program.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SILO PHARMA, INC. Date: April 5, 2024 By: /s/ Eric Weisblum Eric Weisblum Chief Executive Officer 2